Teva Pharmaceuticals is discontinuing its series of digital inhalers starting June 1, 2024.
People who are currently using Digihaler inhalers can continue using them as prescribed until their expiration date. Software and technical support for the apps will end on June 1, 2024.
Teva launched its first digital inhaler, the ProAir Digihaler, in 2019. Digital inhalers have built-in sensors that detect when the inhaler is used. They measure breathing flow and other indicators of asthma control. The devices send data to the companion app that can then be shared with healthcare providers.
Asthma patients who use a Digihaler device should talk with their doctor about alternatives. Inhalers containing the same medications are available. However, patients who use the digital component of the Digihalers may not be able to find an alternative.
The costs of alternative medications you choose may differ from digihalers. Check your health insurance coverage before getting a new inhaler prescription. Find out what brand and generic asthma medications are covered.
Read the full Asthma & Allergy Network article here.
INHALE prepares regular PO and Clinical level newsletters that contain:
Support for the INHALE CQI is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs.
Although Blue Cross Blue Shield of Michigan and the INHALE CQI work in partnership, the opinions, beliefs, and viewpoints expressed by INHALE CQI do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.